deucravacitinib
bms
['ease,(-please),(-disease),(-incrrease),(-decrease)', 'deucra']
phase 2 efficacy and safety of deucravaticinib (tyk2i) in mod-severe sle. met primary endpoint (sri4) for 3mg and 6mg doses (but not 12mg). no signal for hz but increased oral herpes. bigger numbers will be helpful. #acr22 #plenary #acrbest 
Rheumatology nerd. Opinions are my own (except when wrong)